|
MechanismLILRB2 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
[Translation] Phase I clinical study of IO-108 as a single agent and in combination with PD-1 monoclonal antibody
评价IO-108在晚期或转移性实体瘤受试者中的安全性和耐受性,确认中国患者的II期推荐剂量(RP2D);
评价IO-108联合帕博利珠单抗或替雷利珠单抗在晚期或转移性实体瘤患者中的安全性和耐受性,并确认在中国患者中的RP2D;
评价IO-108联合帕博利珠单抗或替雷利珠单抗治疗特定晚期或转移性实体瘤患者的初步抗肿瘤活性。
[Translation] Evaluate the safety and tolerability of IO-108 in subjects with advanced or metastatic solid tumors and confirm the phase II recommended dose (RP2D) for Chinese patients;
To evaluate the safety and tolerability of IO-108 in combination with pembrolizumab or tislelizumab in patients with advanced or metastatic solid tumors and to confirm RP2D in Chinese patients;
To evaluate the preliminary anti-tumor activity of IO-108 in combination with pembrolizumab or tislelizumab in selected patients with advanced or metastatic solid tumors.
100 Clinical Results associated with Immune Onc (Hangzhou) Co., Ltd.
0 Patents (Medical) associated with Immune Onc (Hangzhou) Co., Ltd.
100 Deals associated with Immune Onc (Hangzhou) Co., Ltd.
100 Translational Medicine associated with Immune Onc (Hangzhou) Co., Ltd.